IONTAS Antibody approved for first in patient use in the treatment of B cell Acute Lymphoblastic Leukemia
Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest approved product is a biosimilar monoclonal antibody, eculizumab, indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Generium is the first company in the world to develop and market a biosimilar of eculizumab.